Aiming for a CLL Treatment Home Run Recorded on June 1, 2014
|
|
- Mary Morgan Marsh
- 5 years ago
- Views:
Transcription
1 Patient Power Knowledge. Confidence. Hope. Aiming for a CLL Treatment Home Run Recorded on June 1, 2014 Thomas Kipps, MD, PhD Deputy Director of Research Operations UC San Diego Moores Cancer Center Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That s how you ll get care that s most appropriate for you. Dr. Brian Koffman at ASCO And, Dr. Kipps, you want to introduce yourself? Yes. My name is Dr. Tom Kipps. I'm at the UC San Diego Moores Cancer Center in San Diego, California. One of the things that I beg is not to be left on third base. I mean, I'm very grateful that I'm on the ibrutinib (Imbruvica) and that I've been able to get this deep remission lots of people have. But we were starting to talk about this, and I know this is an area that you're interested in is how do you get somebody from third to home. You know, home may be being starting with MRD negative and you're getting to cure, so if you could kind of touch on that. Well, I think it's really important. I mean, there's a determining factor, which is called minimal residual disease, which is something that you can assess usually after treatment. Now, with drugs such as ibrutinib and other kinase inhibitors, not many patients, very few it's the exception that can achieve what's called complete remission. Now the idelalisib would be in that group. Idelalisib or IPI 145 or other agents that are coming down the pike. ONO There's over 20 now that are being out there, but they are unable to close the deal and like you say get you home, maybe strand you on second or third base. Most patients achieve a partial remission, and the unfortunate thing is when you stop the medicine many patients may experience a relapse of the disease within a very short time, and so it's not a good idea to stop the medicine. However, I think that if we can achieve a perhaps deeper remission and allow you to stop taking the medicine altogether, can some of those patients who achieve that actually achieve a cure? We hope so. Now, we've been working with this compound ABT-199. It's being co-developed by AbbVie and Genentech, and we're very excited about this drug. We've been fortunate to be involved in some of the early trials, and we continue to have many trials with this drug. I'm very impressed with it. It really does target a key facet of the disease. In other words, one of the signature features of this disease is a very high level expression of a protein called BCL2.
2 Yeah, tell us about that. BCL2 is like putting the brake on your cell's ability to die. And so we look at the CLL cell, and it's really a cell on the razor's edge. It has this BCL2 protein, which puts a brake on cell death. But also in CLL they have a mechanism, another protein BIM, which is able to push the cell over the cliff. So it's almost like, sometimes say it's like the flying buttress of the Cathedral of Notre Dame. You have one end going here to die, one end to survive, so that's a balance. And the leukemic cell has been engineered because of the fact that it's a B cell to be on that balance. And the reason for that is that normally B cells have to go through this very tight gauntlet. And if they don't have all the right things that it takes to make a good immune response, they're really programmed to selfdestruct. Now the leukemia cells manage to figure out a way to get beyond that gauntlet and just exist and then to grow. But if you take out BCL2, it's like taking off the flying buttress of the Cathedral of Notre Dame. The whole structure starts to collapse. So it's really critical. So with the identification of these proteins, there's ways of which they have been found to fit together. It's like a lock-key relationship. So if you have these proteins, it's the yin-yang of leukemia. And if you get a small molecule that can actually interface with this, it can take away that lock and allow the protein that's going to cause cell death to do its job. And so it really is quite dramatic because when you add small molecules inhibitors of this protein BCL2 it allows for that internal machinery to take effect, and the cell can undergo cell death. And it's quite specific because CLL cells are wired this way, but the rest of our cells in the body are much more resilient. All right. So this is actually a very targeted therapy, and it's targeted to a known molecular lesion in the cell. I mean, years ago with Carlo Croce and others in the CLL research consortium, some of the genes that are found to be lost in CLL are the ones that can repress the expression of BCL2. So BCL2 expression goes higher and higher, and it gives that mechanism of escape from this gauntlet allowing the leukemic cells to survive. So what it is attacking a very basic principle of leukemia. That's critical because I think what it might do is actually affect maybe potentially eradication of the disease, potentially in some patients. And some of the data has been really exciting. Yes. We've been actually very excited. We have had patients who have failed such therapies as fludarabine (Fludara), cyclophosphine, rituximab (Rituxan) FCR. have failed alemtuzumab (Campath) and did not achieve what's called absence of minimal residual disease. These patients are actually ones that, some of them went into our trial with 199 as a single agent, and they experienced dramatic reductions in their lymph nodes and their white cell count. And when it came right down to it, we couldn't detect any enlarged lymph nodes by CT scan. We did the marrow, and under sensitive methods we could not detect leukemic cells in the marrow. Now, I advocated that we should stop therapy. There was some concern about wanting to continue therapy. But in my mind if we don't have any evidence of disease, why can't we stop the treatment? So we have actually done that in some of our patients, and they have gone on to do well. They haven't had recurrent disease. Some are out since July of last year Wow.
3 And so we're following those patients. But that is very exciting. So the questions that remain with this is how best to use it. As you know, it sometimes in certain patients can be reaching like a tipping point. So patients who have very large tumor burdens, if you completely allow the leukemic cells like the Cathedral of Notre Dame, you can get some collateral damage there. And there have been some deaths. There's been some deaths because, fortunately, not at our institution, but some patients who had very extensive disease, I mean they had lymph nodes the size of a large grapefruit all throughout their body, and, unfortunately, they were on a dose of the medicine and experienced such a dramatic tumor lysis that the contents of the cell released some cells into the blood. And that's really causing problems because, as you know, the insides of the cell are much different than what you have outside the cell. The high potassium levels. Exactly. And that's something that we have to be very careful about. So with the subsequent trials that were opened up after those occurrences, we actually have been monitoring patients very carefully to make sure that they don't have this. And, fortunately, we haven't seen that since we've been implementing steps where we bring the patient actually in the hospital for close monitoring, and I think that's really helped a lot. And have you changed the dosing in terms of how you escalate the dose? Yes. We start with very small doses and take baby steps up and we find the right dose for the patient. And I think at that level and monitor very closely for the tell-tale signs of tumor lysis. The unfortunate thing about tumor lysis is that patients don't have any symptoms at all until you get into disastrous consequences. So the patients may not feel badly at all and so you have to monitor this by taking blood samples. Are patients still required to be hospitalized for taking the pills? No. Actually, when they get acclimated in fact, when these two events occurred, one on the East Coast and one in the Northwest, the trials were put on hold, but we were allowed to continue therapy of our patients. And I had one patient who achieved this MRD-negative complete response in January of last year when the clinical study was put on hold. He did not want to stop therapy, because he felt that if he stopped he might not be able to get back on therapy. And then after numerous discussions with the FDA, the trial was able to open again. And so the trial when it opened in the summer of last year, in 2013, we did another marrow biopsy, and he still was MRD negative. So he elected to stop, and that's when he discontinued therapy. I've been following him ever since, and so far he's not shown any evidence of recurrent disease. And there was another trial that you were involved with, ABT and rituximab. That's correct, yeah. ABT and rituximab and ABT and obinutuzumab (Gazyva), which is a third-generation rituximab, which has been glycoengineered to be even more effective. And there's some new data presented here at ASCO. Can you bring us up to pace on those? Well, I think what we're seeing is that they are experiencing, first there's a complete response rate which is respectable. In terms of getting rid of MRD, we would wish it to be 100 percent, but right now we're seeing in about maybe 25 percent of
4 That's amazing compared to some of the other oral medications. Yes, and why isn't it affecting 100 percent? Those are things we need to find out. And I think that's why even with these advances again, I think it's going to take a combination of approaches, maybe the monoclonal antibodies combined with ABT-199 or different combinations of drugs combined, different dosing regimens. There's a lot of work that needs to be done. I think it would be a mistake right now to say, gee, all this great therapy that's out there, we're done. We're not done. We actually have still a lot of work to do. And I think it's very important, and I don't think we should rest until we can say that this CLL is put into the rear view mirror, and patients can go on their lives. It's embarrassing we can't cure it outright. Any final thought from ASCO 2014 you want to share? I think ASCO 14 here is always good. It's good to see leukemia having some spotlight. But I do say it's exciting from the standpoint of this protein that I mentioned to you before, the ROR1 protein is that we are actually finding it not just on CLL cells, but we're finding it on a variety of other cancer cells, lung cancer, prostate cancer, ovarian cancer. Wow. And it seems to be But only on cancer cells, not on lung tissue, not on Only on cancer cells. prostate tissue, yeah. It seems that it's entwined with the process of metastasis and growth of tumors, which is really very interesting. It's gotten me to think about CLL differently because CLL is really an indolent disease hopefully, primarily but it's also one of the most metastatic diseases on the planet because at diagnosis it's in every lymph node, it's in the bone marrow. So these cancers that have a predilection for metastasis may be expressing this protein. Wasn't it isn't it an embryonic protein? It's an embryonic cell, yes. So that kind of gives a hint that there may be
5 Yes, I think you know, cancer is not an alien from outer space. Cancer is us. And so what I think cancer cells do is they go back to an early program, a tune that we've played before. In other words, when you're developing in the embryo you're a ball of cells, and, fortunately, some of those cells have to metastasize to other parts of the developing embryo to form a nervous system or to form the digestive system. So metastases is inherent in our origin as an organism. And what cancer cells do is they start to play it again and to the detriment because we're not an embryo anymore. But I think if we can hone in on those signals that are used during that process, we might be able to potentially cure cancer in a way that might be far reaching, more than just for the treatment of CLL. I always learn so much when I talk with you, Dr. Kipps. Thanks so much for your time. Thank you very much, Brian. Thank you. Dr. Brian Koffman at ASCO Exciting time in the world of CLL Thank you very much. Good. Boy. That was exciting. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That s how you ll get care that s most appropriate for you.
Dr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014
Patient Power Knowledge. Confidence. Hope. Dr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014 Michael Keating, MB, BS Professor of Medicine, Department of Leukemia
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationDr. Gopal, are you encouraged in the direction of where research is headed and its benefit for patients?
Targeting the Tumor in Lymphoma July 8, 2009 Ajay Gopal Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient
More informationPROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO
PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO 1 00:00:00,067 --> 00:00:10,968 2 00:00:10,968 --> 00:00:12,701 So, you were given a decision aid sheet 3 00:00:12,701 --> 00:00:14,567 about prostate
More informationFine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013
Fine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013 John Corman, M.D. Medical Director, Floyd & Delores Jones Cancer Institute at Virginia Mason Virginia Mason Medical Center
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationAdvances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson. Introduction
Advances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationTracking Genetic-Based Treatment Options for Inflammatory Bowel Disease
Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Recorded on: June 25, 2013 Melvin Heyman, M.D. Chief of Pediatric Gastroenterology UCSF Medical Center Please remember the opinions
More informationBenefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm. Introduction
Benefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationBreast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Introduction
Breast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or
More informationWhat s the Latest in Prostate Cancer Immunotherapy Options?
What s the Latest in Prostate Cancer Immunotherapy Options? Jeri Kim, MD Associate Professor, Department of Geritourinary Medical Oncology The University of Texas MD Anderson Cancer Center Sumit K. Subudhi,
More informationASCO 2016: Ask the Lung Cancer Experts
Live @ ASCO 2016: Ask the Lung Cancer Experts Charu Aggarwal, MD, MPH Assistant Professor of Medicine University of Pennsylvania Health System Liza Villaruz, MD Hematology/Oncology Specialist University
More informationNews from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O.
News from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O. Please remember the opinions expressed on Patient Power are not necessarily the views
More informationEpisode 93: What Role Stem Cells in Leukaemia?
Published on Up Close (https://upclose.unimelb.edu.au) Episode 93: What Role Stem Cells in Leukaemia? What Role Stem Cells in Leukaemia? VOICEOVER Welcome to Up Close, the research, opinion and analysis
More informationHello and welcome to Patient Power sponsored by Northwestern Memorial Hospital. I'm Andrew Schorr.
Brain Tumor Clinical Trials Webcast November 22, 2011 Sean Grimm, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its medical
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I m Andrew Schorr.
The Integrated Approach to Treating Cancer Symptoms Webcast March 1, 2012 Michael Rabow, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationHello and welcome to Patient Power sponsored by UW Medicine Health System. I'm Andrew Schorr
Advanced Techniques for Treating Liver Tumors Webcast James O. Park, M.D. Veena Shankaran, M.D. Raymond S.W. Yeung, M.D., FRCS(C), FACS Derek Epps November 28, 2011 Please remember the opinions expressed
More informationMinimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients
Minimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients Recorded on: August 1, 2012 Venu Pillarisetty, M.D. Surgical Oncologist Seattle Cancer Care Alliance Please remember the opinions
More informationand MS: Mood Changes For those
MS Learn Online Featuree Presentation Mood Changes and MS: The Rolee of Healthy Grieving Featuring: Sarah Minden, MD; David Rintell, PhD; Rosalind Kalb, PhD Cathy: I hate the phrase of, "Well, you look
More informationBreakthrough Understanding in Pancreatic Cancer Therapy
Breakthrough Understanding in Pancreatic Cancer Therapy Recorded on: May 28, 2013 Sunil R. Hingorani, M.D., Ph.D. Associate Member Fred Hutchinson Cancer Research Center Please remember the opinions expressed
More informationRobotic Surgery: A Better Option for Many Head & Neck Cancers
Robotic Surgery: A Better Option for Many Head & Neck Cancers Neal Futran, MD, DMD Director of Head and Neck Surgery, Department of Otolaryngology UW Medicine Eduardo Mendez, MD Assistant Professor, Otolaryngology:
More informationAutoimmune disorders: An emerging risk factor for CV disease
Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's
More informationSurgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland. Introduction
Surgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance,
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationKeeping Hope Alive: Alternative Options for Bone Marrow Transplant Webcast February 9, 2011 Paul O'Donnell, M.D., Ph.D. Ronni Maestas Jessie Quinn
Keeping Hope Alive: Alternative Options for Bone Marrow Transplant Webcast February 9, 2011 Paul O'Donnell, M.D., Ph.D. Ronni Maestas Jessie Quinn Please remember the opinions expressed on Patient Power
More informationHow a CML Patient and Doctor Work Together
How a CML Patient and Doctor Work Together Recorded on: November 5, 2012 Jessica Altman, M.D. Assistant Professor, Department of Medicine, Hematology Oncology Division Feinberg School of Medicine, Northwestern
More informationAs a Lung Cancer Patient, What Information Do I Need to Make the Best Choices?
As a Lung Cancer Patient, What Information Do I Need to Make the Best Choices? Mary Ellen Hand, RN, BSN Nurse Coordinator Rush University Medical Center Emma Shtivelman, PhD Chief Scientist Cancer Commons
More informationConnecting With the Virtual CLL Community
Connecting With the Virtual CLL Community Lisa Minkove CLL Patient and Advocate Andrew Schorr CLL Patient and Patient Power Co-Founder Stella and Len Care Partner and CLL Patient Patrick CLL Patient Please
More informationSection 4 Decision-making
Decision-making : Experience of health professional communication Conversations about s Participants were asked to describe the conversations they have had about mitochondrial disease options. The most
More information11 INSTRUCTOR GUIDELINES
STAGE: Recent Quitter Ms. Barnes is a 28-year-old woman who has been filling her oral contraceptive prescription at your pharmacy for the past 6 years. Four months ago, you assisted her in quitting smoking
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 9 - Transcript - pg. 1 How to Foster Post-Traumatic Growth Are Some Clients Predisposed for Post-Traumatic Growth? with Christine Padesky, PhD; Ron Siegel, PsyD;
More informationMarty: I had my physical in 2006, and my physician said that I had myelofibrosis and said I had three to five years to live.
Advances in the Treatment of Myeloproliferative Disorders Webcast April 28, 2009 Srdan Verstovsek, M.D., Ph.D. Marty Prager Please remember the opinions expressed on Patient Power are not necessarily the
More informationLiving With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel. Steve s Story
Living With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power.
More informationHereditary Cancer Syndromes and the Obstetrician/Gynecologist
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/hereditary-cancer-syndromes-and-theobstetriciangynecologist/6990/
More informationAndrew Schorr: And you're a retired businessman. Tell us about this diagnosis. What was going on for you that suddenly you were sick? What happened?
Advances in the Treatment of Stomach Cancer Webcast August 5, 2008 Linus Ho, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationCourtesy of RosenfeldInjuryLawyers.com (888)
CROSS-EXAMINATION BY MR. BERGER: Q DR. WATFORD, WE HAVE MET TWICE BEFORE. DO YOU RECALL THAT? Q ONCE IN YOUR IN DECEMBER, AND YOU WERE KIND ENOUGH TO MEET WITH US? Q ONCE IN JANUARY WHEN WE BROUGHT YOU
More informationComparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Daniel Ferrante
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/comparing-liquid-based-cytology-methodsdetection-cervical-cancer-perspectives-dr-daniel-ferrante/7592/
More informationWEEK 1: Feedback from Helen and Melissa - Friday 17 March 2017
Food As Medicine WEEK 1: Feedback from Helen and Melissa - Friday 17 March 2017 https://youtu.be/irvpha-bmwy HELEN TRUBY: Hi, everyone. Welcome to "Food as Medicine," week one Feedback. I'm Helen Truby
More informationOne of the areas where it's certainly made it difference is with the transplantation of the liver. Dr. Roberts thinks so much for joining us.
Benefits and Risks of Living Donor Liver Transplant Webcast May 28, 2008 John Roberts, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationBeyond The Data: Promoting Well-being in Older Adults
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/grand-rounds-nation/beyond-data-promoting-well-being-olderadults/9844/
More informationMyeloma Myth Busters: Clinical Trials
Patient Power Knowledge. Confidence. Hope. Myeloma Myth Busters: Clinical Trials Recorded on December 8, 2014 Paul Richardson, MD Clinical Director, Jerome Lipper Center for Multiple Myeloma Dana-Farber
More informationCecile Nunley Breast Cancer Survivor Story
Cecile Nunley Breast Cancer Survivor Story Breast Cancer Survivor My Personal Story I was diagnosed with stage III breast cancer on April 27, 2012 in Sacramento, California. Writing that sentence is very
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationClinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer
Clinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer Questions Answered by Andrea Apolo, MD is a Lasker Clinical Research Scholar and tenure-track
More informationUnderstanding Acute Kidney Injury and Its Impact
Understanding Acute Kidney Injury and Its Impact Recorded on: March 7, 2013 Chi-Yuan Hsu, M.D., M.S. Chief of the Division of Nephrology, UCSF Department of Medicine UCSF Medical Center Raymond Hsu, M.D.
More informationHIV Housing Care Continuum Webinar 1 August 3, 2016
Page 1 HIV Housing Care Continuum August 3, 2016 Rita Flegel: Hello and welcome. I'm Rita Flegel, the Director of HUD's Office of HIV/AIDS Housing. And presenting with me today is Amy Palilonis also from
More informationTargeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr
Targeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationSurgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte. Mike s Story
Surgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationHello and welcome to Patient Power sponsored by the Seattle Cancer Care Alliance. I'm Andrew Schorr.
New Hope For Melanoma Webcast April 6, 2011 Kim Margolin, M.D. David Byrd, M.D. Kathy Sparks Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care
More informationDetecting Coronary Artery Disease: The Role of Non-Invasive Cardiac Stress Testing Webcast September 28, 2010 Preeti Kansal, M.D.
Detecting Coronary Artery Disease: The Role of Non-Invasive Cardiac Stress Testing Webcast September 28, 2010 Preeti Kansal, M.D. Please remember the opinions expressed on Patient Power are not necessarily
More informationDiabetes Remission with Weight Loss - Frankly Speaking EP 49
Diabetes Remission with Weight Loss - Frankly Speaking EP 49 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More informationThe Current Research on Stretching and Flexibility is Flawed!
Transcript from: https://www.youtube.com/watch?v=qz0ot7tbbg0 Original Article: http://stretchcoach.com/articles/proper-stretching/ The Current Research on Stretching and Flexibility is Flawed! Hi. I'm
More informationIntroduction. All Rights Reserved
Sarcoma: Patients and Doctors Working Together to Fight a Rare Cancer Health Radio Network February 4, 2007 Chappie Conrad III, M.D., F.A.C.S. Douglas Hawkins, M.D. Jared Holmes Please remember the opinions
More informationVIDEO_ Sarah Hallberg - Interview (San Diego 2017)
VIDEO_ Sarah Hallberg - Interview (San Diego 2017) Dr. Andreas Eenfeldt: If you are a doctor and you want to help your patients with type 2 diabetes to reverse their disease, how do you do it? You can
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I'm Andrew Schorr.
Managing Pain from Shingles Webcast August 22, 2011 George Pasvankas, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff
More informationCharlie: I was just diagnosed with CLL, so my doctor and I are now in the process of deciding what
Track 3: Goals of therapy Charlie: I was just diagnosed with CLL, so my doctor and I are now in the process of deciding what treatment I ll have. My doctor told me there are several factors she will use
More informationFelden-WHAT? By Lawrence Wm. Goldfarb , All Rights Reserved
Felden-WHAT? By Lawrence Wm. Goldfarb 1993-94, All Rights Reserved It was about to happen; that moment, that dreaded moment. I was at my friend Marcello's birthday party, enjoying the Brazilian music when
More informationCognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Introduction
Cognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of
More informationUpper Tract Urothelial Carcinomas (UTUCs)
Upper Tract Urothelial Carcinomas (UTUCs) Part II: UTUC Treatment Options November 14, 2017 Moderated by: Presented by: Gary D. Steinberg, MD University of Chicago Medical Center Ahmad Shabsigh, MD Ohio
More informationProgress and Promises of Leukemia Therapy Webcast December 14, 2010 Olga Frankfurt, M.D. Christy Moore. Introduction
Progress and Promises of Leukemia Therapy Webcast December 14, 2010 Olga Frankfurt, M.D. Christy Moore Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern
More informationLet me introduce you to her. That s Barbara Scribner who joins us from Kent, Washington. Barbara, thank you so much for joining us.
Lung Cancer: Detection and Early Intervention Webcast November 30, 2009 Douglas E. Wood, M.D. Jason Chien, M.D., M.S. Barbara Scribner Please remember the opinions expressed on Patient Power are not necessarily
More informationFostering a "Back to Basics" Model in Type 2 Diabetes Care
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/diabetes-discourse/fostering-a-back-to-basics-model-for-type-2-
More informationClinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II
Clinical Trials: Non-Muscle Invasive Bladder Cancer Tuesday, May 17th, 2016 Part II Presented by Yair Lotan, MD is holder of the Helen J. and Robert S. Strauss Professorship in Urology and Chief of Urologic
More informationThe Parent's Perspectives on Autism Spectrum Disorder
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/autism-spectrum/the-parents-perspectives-on-autism-spectrumdisorder/6809/
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationLung Cancer Awareness Month Update 2008
Lung Cancer Awareness Month Update 2008 Guest Expert: Frank, MD Professor of Thoracic Surgery Lynn, MD Professor of Pulmonary Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationCarrier Screening in your Practice Is it Time to Expand your View?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/carrier-screening-your-practice-it-time-expandyour-view/9648/
More informationRecording Transcript Wendy Down Shift #9 Practice Time August 2018
Recording Transcript Wendy Down Shift #9 Practice Time August 2018 Hi there. This is Wendy Down and this recording is Shift #9 in our 6 month coaching program. [Excuse that I referred to this in the recording
More informationAfter Adrenal Cancer Treatment
After Adrenal Cancer Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. Lifestyle Changes After Treatment for Adrenal Cancer
More informationUnderstanding Acute Leukemias
Understanding Acute Leukemias Guest Expert: Peter, MD Associate Professor of Hematology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr. Francine. I am Bruce
More informationShoulder Arthritis and Shoulder Replacement Surgery Webcast June 22, 2010 Matthew Saltzman, M.D. Introduction
Shoulder Arthritis and Shoulder Replacement Surgery Webcast June 22, 2010 Matthew Saltzman, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial
More informationRoles of Non-HDL Cholesterol in Risk Assessment and Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/roles-of-non-hdl-cholesterol-in-risk-assessment-andtreatment/7066/
More informationPelvic Organ Prolapse: What Can I Do About This Problem? Webcast July 27, 2010 Christina Lewicky-Gaupp, M.D. Joanne s Story
Pelvic Organ Prolapse: What Can I Do About This Problem? Webcast July 27, 2010 Christina Lewicky-Gaupp, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern
More informationRecognizing Dissociative Disorders
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/recognizing-dissociative-disorders/3551/
More informationParkinson s Disease: An Update Webcast November 27, 2007 Cindy Zadikoff, M.D.
Parkinson s Disease: An Update Webcast November 27, 2007 Cindy Zadikoff, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its
More informationOvercoming Seasonal Affective Disorder Webcast December 19, 2011 Pamela Sheffield, M.D. Crystal Wong, M.D.
Overcoming Seasonal Affective Disorder Webcast December 19, 2011 Pamela Sheffield, M.D. Crystal Wong, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine,
More informationPlease Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222.
Announcer: Please Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222. Welcome to Stay Happily Married, your source for weekly updates on the latest tips and
More informationAndrew Schorr: What treatment have you had, Gaye, then in that interim four years? What's happened?
Navigating Sarcoma Treatments Health Radio June 20, 2007 Christopher Ryan, M.D. Kevin Norwood, M.D. Angela Lim, LICSW, OSW-C Gaye Johnson Please remember the opinions expressed on Patient Power are not
More informationHow to Work with the Patterns That Sustain Depression
How to Work with the Patterns That Sustain Depression Module 5.2 - Transcript - pg. 1 How to Work with the Patterns That Sustain Depression How the Grieving Mind Fights Depression with Marsha Linehan,
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 3 - Transcript - pg. 1 How to Foster Post-Traumatic Growth The Critical Role of Connection in Post-Traumatic Growth with Sue Johnson, EdD; Kelly McGonigal, PhD;
More informationInterview - Jon Cohen Kaiser Family Foundation July 23, 2012
Transcript provided by the 1 (Tip: Click on the binocular icon to search this document) Interview - Jon Cohen July 23, 2012 2 [START RECORDING] JACKIE JUDD: Jon Cohen of Science Magazine, welcome. The
More informationFile No WORLD TRADE CENTER TASK FORCE INTERVIEW FIREFIGHTER MIKE ZECHEWYTZ. Interview Date: December 5, Transcribed by Nancy Francis
File No. 9110242 WORLD TRADE CENTER TASK FORCE INTERVIEW FIREFIGHTER MIKE ZECHEWYTZ Interview Date: December 5, 2001 Transcribed by Nancy Francis 2 CHIEF LAKIOTES: Today is December 5th, 2001. The time
More informationChronic Lymphocytic Leukemia (CLL): Advances in Research and Treatment Health Radio April 16, 2007 Michael Keating, M.B., B.S.
Chronic Lymphocytic Leukemia (CLL): Advances in Research and Treatment Health Radio April 16, 2007 Michael Keating, M.B., B.S. Please remember the opinions expressed on Patient Power are not necessarily
More informationJourney to Recovery: A Breast Cancer Podcast Series Episode 1, Part 1: A Breast Cancer Diagnosis
Journey to Recovery: A Breast Cancer Podcast Series Episode 1, Part 1: A Breast Cancer Diagnosis Doreen: When I was diagnosed with breast cancer, I felt shocked --extremely shocked -- and I felt like I
More informationStatin Intolerance: Keys to Patient Counseling and Guidance
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/statin-intolerance-keys-to-patient-counseling-andguidance/7076/
More informationAn Update on BioMarin Clinical Research and Studies in the PKU Community
An Update on BioMarin Clinical Research and Studies in the PKU Community Barbara Burton, MD, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Director of PKU Clinic, Children
More informationSECOND TRADITION SKIT
SECOND TRADITION SKIT NARRATOR Welcome to the presentation of our skit on Al Anon's Second Tradition. I am Dolly Delegate and I'd like to introduce you to our cast. DOLLY DELEGATE AUDREY AUTHORITY BOSSY
More informationMS Learn Online Feature Presentation MS and Your Emotions, part two Deborah Miller, PhD. Tracey>> Welcome to MS Learn Online, I m Tracey Kimball.
Page 1 MS Learn Online Feature Presentation MS and Your Emotions, part two Deborah Miller, PhD Tracey>> Welcome to MS Learn Online, I m Tracey Kimball. Tom>> and I m Tom Kimball. In the first installment
More informationHerpes Zoster Vaccination: New Recommendations for Shingles Prevention - Frankly Speaking EP 50
Herpes Zoster Vaccination: New Recommendations for Shingles Prevention - Frankly Speaking EP 50 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible
More informationA CLL Expert Roundtable: Treatment News From ASH 2018
Patient Power Knowledge. Confidence. Hope. A CLL Expert Roundtable: Treatment News From ASH 2018 Nitin Jain, MD Assistant Professor, Department of Leukemia, Division of Cancer Medicine The University of
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationInformation for Patients with Chronic Lymphocytic Leukemia
Slide 1. Welcome & Introductions OPERATOR: Greetings, and welcome to Information for Patients with, telephone and web education program. It is now my pleasure to introduce your moderator Lizette Figueroa-Rivera.
More informationExpert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Introduction
Expert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine, their staff,
More informationHow to Work with the Patterns That Sustain Depression
How to Work with the Patterns That Sustain Depression Module 2.1 - Transcript - pg. 1 How to Work with the Patterns That Sustain Depression How to Break the Depression-Rigidity Loop with Lynn Lyons, LICSW;
More informationAfter Soft Tissue Sarcoma Treatment
After Soft Tissue Sarcoma Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. What Happens After Treatment for Soft Tissue Sarcomas?
More informationSurgical Treatment For Pancreatic Cancer Webcast March 22, 2011 Venu Pillarisetty, M.D. Stan Barer. Introduction
Surgical Treatment For Pancreatic Cancer Webcast March 22, 2011 Venu Pillarisetty, M.D. Stan Barer Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationThe Treatment Landscape for Metastatic Breast Cancer Webcast Host: Andrew Schorr Guests: Hope Rugo, M.D. Robert Prosnitz, M.D.
The Treatment Landscape for Metastatic Breast Cancer Webcast Host: Andrew Schorr Guests: Hope Rugo, M.D. Robert Prosnitz, M.D. Dikla Benzeevi Please remember the opinions expressed on Patient Power are
More informationEmerging Trends in the Sequencing and Combination of Therapies for Advanced Melanoma ReachMD Page 1 of 13
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information